Legend Holdings and Kawin Technology-backed Sciwind topped up its coffers in a series C round to advance its metabolic disease drug pipeline.

Sciwind Biosciences, a China-based metabolic disease therapy developer backed by conglomerate Legend Holdings and pharmaceutical firm Kawin Technology, closed a $70m series C round on Tuesday.

Venture capital group IDG Capital led the round and was joined by Lyfe Capital and Loyal Valley Capital.

Founded in 2017, Sciwind is developoing specialised treatments for metabolic conditions such as type 2 diabetes, obesity, liver fibrosis and non-alcoholic steatohepatitis. The cash will fund clinical trials of its XW003, XW004 and XW014 drug candidates…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Fernando Moncada Rivera

Fernando Moncada Rivera is a reporter at Global Corporate Venturing and also host of the CVC Unplugged podcast.
Email LinkedIn